409 ILLINOIS STREET, SAN FRANCISCO, CA
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Amendments to Articles of Incorporation or Bylaws, Other Events
Financial Results, Press Release
Other Events
Unaudited Pro Forma Condensed Consolidated Financial Information
Completes Sale of China to AstraZeneca for Approximately $220 Million
Approval of Sale of China to AstraZeneca by the China State Administration for Market Regulation
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence